Related Experiment Video
Updated: Jun 12, 2026
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer
Firat Baris Barlas1,2, Bilge Olceroglu2, Didem Ag Seleci3
1Institute for Technical Chemistry, Leibniz University Hannover, Hannover, Germany.
Background:
Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches.
Objective:
This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells.
Methods:
The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells.
Results:
The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297).
Conclusion:
The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.
Insights
This study developed a targeted cancer therapy using a doxorubicin and cisplatin (Dox-Cis) conjugate encapsulated in MUC-1 aptamer-modified niosomes. The novel formulation showed improved anticancer efficacy, especially in MUC-1 positive cancer cells.
Area of Science:
- Nanomedicine
- Drug Delivery Systems
- Cancer Therapeutics
Background:
- Cancer affects millions globally, necessitating novel treatment strategies.
- Current research focuses on combination therapies and targeted drug delivery.
- Developing effective and biocompatible cancer treatments remains a critical challenge.
Purpose of the Study:
- To create and evaluate a novel drug delivery system for cancer treatment.
- To investigate the anticancer efficacy of a doxorubicin and cisplatin (Dox-Cis) conjugate.
- To enhance drug targeting and biocompatibility using MUC-1 aptamer-modified niosomes.
Main Methods:
- Characterization of the Dox-Cis conjugate using FTIR and LC-Q-TOF/MS.
- Assessment of niosomal vesicle properties (zeta potential, morphology) via DLS and TEM.
- In vitro evaluation of cell viability and apoptosis on MUC-1 positive (HeLa) and negative (U87) cancer cells.
Main Results:
- Successful synthesis and encapsulation of the Dox-Cis conjugate within niosomes.
- The Nio/Dox-Cis/MUC-1 formulation exhibited superior anticancer activity compared to individual drugs or unencapsulated combinations.
- Targeted delivery demonstrated greater efficacy on MUC-1 positive HeLa cells (38.503 ± 1.407) versus MUC-1 negative U87 cells (46.653 ± 1.297).
Conclusions:
- The MUC-1 aptamer-conjugated niosomal Dox-Cis system shows significant potential as a targeted cancer therapy.
- This approach offers a promising avenue for developing more effective and personalized cancer treatments.
- Targeted drug delivery platforms can enhance therapeutic outcomes and minimize off-target effects.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
